# HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

> **NCT05751044** · PHASE1,PHASE2 · RECRUITING · sponsor: **Princess Maxima Center for Pediatric Oncology** · enrollment: 26 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Venetoclax
- **DRUG:** Dexamethasone
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** intrathecal chemotherapy

## Key facts

- **NCT ID:** NCT05751044
- **Lead sponsor:** Princess Maxima Center for Pediatric Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2032-02-01
- **Final completion:** 2032-02-01
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05751044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05751044, "HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05751044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*